Zynerba Pharma (ZYNE) Reports Q3 Loss of $0.63/Share

Zynerba Pharma (NASDAQ: ZYNE) reported Q3 EPS of ($0.63), versus ($0.67) reported last year.

Financial Outlook

The Company believes that the cash and cash equivalent position of $66.3 million as of September 30, 2017 is sufficient to develop five Phase 3-ready programs and initiate at least one pivotal program and fund operations and capital requirements into 2019

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c